https://www.live-feeds.com/feed/uniqure-stock-crashes-as-huntington-s-gene-therapy-data-weakenContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/uniqure-stock-crashes-as-huntington-s-gene-therapy-data-weakenhttps://www.live-feeds.com/feed/uniqure-stock-crashes-as-huntington-s-gene-therapy-data-weaken#u94357Fri, 02 Oct 2026 09:26:54 +0000Shares of gene therapy developer uniQure crashed after the company released an updated data readout for its experimental Huntington's disease treatment, ifezuntirgene inilparvovec, also known as AMT-130. Although the therapy continued to show a dose-dependent slowing of disease progression through 48 months, it failed to hit statistical significance on a primary clinical measure. The missed statistical endpoint triggered a massive sell-off among investors and sent partner ClearPoint Neuro shares down 24 percent.Why it mattersThe experimental treatment is being evaluated in an ongoing Phas